With More 2024 FDA Filings Planned, Novartis Drug Starts Showing Blockbuster Potential
Novartis drug iptacopan, which won its first FDA approval in early December in a rare blood disorder, has met the main goal of a pivotal test in an ultra-rare kidney disease. The small molecule’s potential to address many diseases has stirred up blockbuster expectations.
Source: medcitynews.com